StockData

Exelixis vs Halozyme Therapeutics

EXEL and HALO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EXEL and HALO compare

Exelixis is the larger company, worth 1.5 times as much as Halozyme Therapeutics ($16.8B against $11.4B).

On earnings, Exelixis is cheaper: it trades at 20.7× trailing earnings, against 25.3× for Halozyme Therapeutics.

Halozyme Therapeutics grew revenue faster over the last twelve months (45.0% versus 9.1% for Exelixis).

Exelixis keeps more of each dollar of sales as profit, with a net margin of 35.5% compared with 26.9% at Halozyme Therapeutics.

Exelixis scores higher on the StockData Score (18 against 13 for Halozyme Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEXELHALO
Size and price
Market cap$16.8B$11.4B
Share price$69.00$100.27
Change, 1 year58.3%42.0%
Change, 5 years283%182%
Beta (5Y)0.720.74
Employees1,077423
StockData Score
Total score18 (better)13
Valuation score3 (better)0
Growth score34 (better)
Performance score6 (better)5
Health score6 (better)4
Dividend score00
Valuation
P/E20.7× (better)25.3×
P/S6.7×6.3× (better)
P/B9.2×–
EV/EBITDA15.5× (better)19.7×
P/FCF14.5×12.8× (better)
PEG0.29 (better)1.19
FCF yield6.9%7.8% (better)
Fair value$68.48$83.32
Margin of safety−0.76% (better)−20.3%
Growth
Revenue growth (TTM)9.1%45.0% (better)
Revenue growth, 5Y average18.6%39.2% (better)
Net income growth (TTM)30.6% (better)−18.5%
EPS growth (TTM)40.9% (better)−16.4%
EPS growth, 5Y average51.4% (better)23.0%
Profitability
Gross margin96.3% (better)82.3%
Operating margin40.2% (better)37.4%
Net margin35.5% (better)26.9%
FCF margin46.5%49.1% (better)
Return on equity44.3%216% (better)
Return on invested capital75.0% (better)26.6%
Financial health
Debt / equity0.00–
Net debt / EBITDA–3.21
Interest coverage–30.6×
Current ratio3.213.88 (better)
Altman Z-score17.46 (better)3.54
Piotroski F-score7 (better)5
Dividends and buybacks
Buyback yield7.5%–
Shareholder yield7.5% (better)0.00%
Ownership
Held by institutions106%109%
Held by insiders9.0%1.3%
Insider net buying, 12 months−$31.8M (better)−$43.8M
Short interest, % of float11.5%12.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.